CHD1L (chr1 helicase DNA binding protein 1-like) is an ATP-dependent chr1 remodeling enzyme that plays critical roles in DNA damage repair and cancer progression 1. The protein functions as a chr1 remodeler by catalyzing nucleosome sliding away from DNA breaks in an ATP-dependent manner, facilitating DNA repair processes 1. CHD1L is recruited to DNA damage sites through interaction with poly-ADP-ribose, specifically recognizing histones that are poly-ADP-ribosylated following DNA damage 1. Beyond DNA repair, CHD1L acts as an oncogene that promotes tumor progression through multiple mechanisms including unleashed cell proliferation, G1/S cell cycle transition, and inhibition of apoptosis 1. The protein disrupts cell death programs by binding apoptotic proteins and activating the AKT pathway through upregulation of target genes such as SPOCK1 and TCTP 1. Meta-analysis of 2,720 patients across 15 studies demonstrates that high CHD1L expression correlates with poor overall survival, advanced TNM stage, larger tumor size, poor differentiation, and distant metastasis 2. CHD1L overexpression occurs across multiple solid tumor types and serves as an independent biomarker for tumor progression and prognosis 23. Recent studies have also identified pathogenic CHD1L variants associated with Müllerian duct anomalies, expanding its clinical relevance beyond oncology 4.